Filing Flows › Comparisons › PGEN vs VNDA
Precigen vs Vanda Pharmaceuticals: PGEN and VNDA compared
Precigen is the larger company: $74.1M of revenue in its latest quarter (Q3 2026) against $69.8M for Vanda Pharmaceuticals (Q3 2026). Precigen is growing faster (25× against +24% a year earlier). Precigen is more profitable, with an operating margin of 52.1% against -33.7%.
Where the money goes: PGEN and VNDA
Precigen (PGEN) · Q3 2026
Precigen, Q3 2026: revenue $74.1M (25× year over year), operating margin 52.1%, net earnings $35.8M, operating cash flow $11.9M. The chart follows the revenue to costs, profit and cash.
Vanda Pharmaceuticals (VNDA) · Q3 2026
Vanda Pharmaceuticals, Q3 2026: revenue $69.8M (+24% year over year), operating margin -33.7%, net loss $22.6M, operating cash flow −$28.4M. The chart follows the revenue to costs, profit and cash.
| Precigen (PGEN) | Vanda Pharmaceuticals (VNDA) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $74.1M | $69.8M |
| Revenue growth, Y/Y | 25× | +24% |
| Operating margin | 52.1% | -33.7% |
| Net earnings | $35.8M | −$22.6M |
| Net margin | 48.2% | -32.3% |
| Operating cash flow | $11.9M | −$28.4M |
| Free cash flow | $11.4M | — |
Where the revenue comes from
Precigen
- Product revenues, net: $73.0M (98%)
- Service revenues: $1.2M (2%)
Vanda Pharmaceuticals
- Fanapt®: $38.8M (56%)
- HETLIOZ® net product sales: $21.7M (31%)
- PONVORY® net product sales: $7.7M (11%)
- NEREUSTM: $1.6M (2%)
Questions
Which is bigger, Precigen or Vanda Pharmaceuticals?
Precigen is the larger company: $74.1M of revenue in its latest quarter (Q3 2026) against $69.8M for Vanda Pharmaceuticals (Q3 2026).
Is Precigen or Vanda Pharmaceuticals growing faster?
Precigen is growing faster (25× against +24% a year earlier).
Which is more profitable, Precigen or Vanda Pharmaceuticals?
Precigen is more profitable, with an operating margin of 52.1% against -33.7%.
More: Precigen earnings · how Precigen makes money · Vanda Pharmaceuticals earnings · how Vanda Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.